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MBD5‑associated neurodevelopmental disorder (MAND) is an autism spectrum disorder (ASD) 
characterized by intellectual disability, motor delay, speech impairment and behavioral problems; 
however, the biological role of methyl‑CpG‑binding domain 5, MBD5, in neurodevelopment and 
ASD remains largely undefined. Hence, we created neural progenitor cells (NPC) derived from 
individuals with chromosome 2q23.1 deletion and conducted RNA‑seq to identify differentially 
expressed genes (DEGs) and the biological processes and pathways altered in MAND. Primary skin 
fibroblasts from three unrelated individuals with MAND and four unrelated controls were converted 
into induced pluripotent stem cell (iPSC) lines, followed by directed differentiation of iPSC to NPC. 
Transcriptome analysis of MAND NPC revealed 468 DEGs (q < 0.05), including 20 ASD‑associated 
genes. Comparison of DEGs in MAND with SFARI syndromic autism genes revealed a striking 
significant overlap in biological processes commonly altered in neurodevelopmental phenotypes, with 
TGFβ, Hippo signaling, DNA replication, and cell cycle among the top enriched pathways. Overall, 
these transcriptome deviations provide potential connections to the overlapping neurocognitive and 
neuropsychiatric phenotypes associated with key high‑risk ASD genes, including chromatin modifiers 
and epigenetic modulators, that play significant roles in these disease states.
Autism spectrum disorder (ASD) is an encompassing term that describes neurodevelopmental disorders that 
have common deficits in communication and social interactions, accompanied by stereotyped behaviors and 
restricted interest. The exact molecular mechanism(s) that leads to this clinical entity is unknown. Studies sug-
gest that between 20 and 45% of all ASDs are associated with rare pathogenic variants in specific  genes1,2. The 
use of chromosomal microarray (CMA) is advocated as the first tier genetic test for individuals with  ASD3,4.
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The utilization of CMA led to the identification of MBD5-associated neurodevelopmental disorder (MAND, 
MIM 156200), which is an ASD characterized by intellectual disability, motor delay, severe speech impairment, 
and behavioral  problems5. MAND serves as an umbrella term that encompasses 2q23.1 deletion syndrome, MBD5 
variant cases, and 2q23.1  duplications5. The conditions in this group of disorders have copy number variations or 
pathogenic sequence variants in the methyl-binding domain 5 gene (MBD5, MIM 611472), which is responsible 
for the majority of the phenotypes present in  MAND6,7. MBD5 variants have been associated with ASD, epilepsy, 
and schizophrenia in multiple  cohorts7,8. The pathological mechanisms and pathways underlying the primarily 
neurological, neurodevelopmental, and neurobehavioral aspects of the MAND phenotype are not well delineated. 
Deficiency of Mbd5 in mice resulted in reduced body weight motor deficits, abnormal social behavior, impaired 
learning, and iron metabolism  abnormalities9,10. However, the importance of the genes associated with MAND 
in specific neurodevelopmental functions remains largely undefined.
Utilization of animal models to understand autism and other human neurodevelopmental or psychiatric 
disorders proves to be  difficult11. Further, the absence of the “perfect” animal model leads to the inability to 
truly understand the human pathological mechanism which can lead to potential therapeutic  targets12,13. Recent 
studies utilizing stem cell technology to derive neurons has served as the popular method to model neurodevel-
opmental disorders and has revealed deeper understanding of the phenotype of these  disorders13–15. In addition, 
next-generation RNA-sequencing (RNA-seq) has been utilized in numerous studies and is a valid tool to identify 
therapeutic targets, biomarkers, pathways, and genes associated with ASD modeled by stem cell-derived human 
 neurons16–19.
In this study, we explore the underpinnings of the neurodevelopmental phenotype of MAND by creating 
neural progenitor cells (NPC) derived from patients with 2q23.1 deletion syndrome, followed by RNA-seq to 
identify the contributing molecular pathways. Data show that haploinsufficiency of one or more genes the 2q23.1 
region leads to FOXG1 upregulation in NPC, accompanied with differentially expressed genes implicated in 
forebrain regionalization in early neurogenesis. Altered genes significantly overlap with ASD-associated genes, 
providing further insight into mechanisms underlying ASD by identifying shared network perturbances caused 
by the genetically penetrant MAND-associated 2q23.1 deletion.
Materials and methods
This study was approved by the Baylor College of Medicine Institutional Review Board. All samples and infor-
mation were collected after obtaining written informed consent. Whole blood and skin samples were provided 
by each participant. Participant recruitment, sample collection, and all experiments were performed in accord-
ance with relevant guidelines and regulations by the Baylor College of Medicine Institutional Review Board and 
associated regulatory committees.
Primary cell culture. Primary skin fibroblast cells were derived and cultured in DMEM (Thermo) contain-
ing 10% FBS, 1% non-essential amino acids, 2 mM glutamine, 0.1 mM 2-mercaptoethanol, and 4 ng/ml human 
recombinant FGF2 (in house)20. Fibroblasts and NPC lines utilized in this study were obtained from four con-
trols (CTR1,  CTR221, CTR3, CTR4) and three MAND patients with confirmed molecular diagnosis of 2q23.1 
deletion syndrome by chromosomal microarray (Fig. 1a, Supplementary Table 1)22–24. MAND1 (SMS388, 3 y 
old female) has a 0.73 Mb loss at 2q22.3q23.1, 46,XX.arr[hg19]2q22.3q23.1(148,345,483–149,080,197) × 1,15q11
.1q11.2(20,262,223–22,285,757) ×  16,25. MAND2 (SMS447, 10 y male) has a 0.18 Mb 2q23.1 deletion, 46,XY.arr
[hg19]2q23.1(148,687,657–148,872,174) × 1. MAND3 (SMS456, 8 y female) has a 3.43 Mb deletion at 2q23.1, 
46,XX.arr[hg19]2q22.3-q23.3(148,326,568–151,757,065) ×  125. All MAND cases were confirmed to have haplo-
insufficiency of MBD5 (Fig. 1b).
Reprogramming skin fibroblasts into iPSC with episomal plasmids. Early passages (between pas-
sages p3 and p5) of skin fibroblasts were cultured at low oxygen atmosphere of 4%  O2/5%  CO2/91%  N2 and 
maintained in the condition for the entire reprograming period to enhance iPSC  generation21,26. Episomal vec-
tors carrying shRNA for p53 suppression and non-transforming MYCL, in addition to the usual reprogramming 
genes, POU5F1, SOX2, KLF4, and LIN28 were employed to reprogram the  fibroblasts27. Three micrograms of 
combined episomal plasmids (Addgene 27077, 27078 and 27080) were electroporated into 6 ×  105 fibroblast 
cells by using a Nucleofector II device (Lonza) and an Amaxa NHDF Nucleofector kit (Lonza) according to the 
manufacturer’s  instructions28. The electroporated cells were allowed to recover for 2 to 4 days by culturing in the 
above conditions. Cells (2 ×  105) were placed into 100 mm dishes previously coated with Matrigel (BD Biosci-
ence). The following day the culture medium was switched to  mTeSR129 (STEMCELL Technologies). Colonies 
emerged about 14 days post-transduction. Colonies were mechanically isolated around day 20 and expanded 
under feeder free conditions in mTeSR1 medium on a Matrigel coated substratum.
Neural progenitor cell (NPC) differentiation. NPC lines were generated from iPSCs through mon-
olayer culture protocol using STEMdiff Neural Induction Medium (StemCell Technologies), following the man-
ufacturer’s instructions. Briefly, 2 ×  106 iPSCs were transferred onto Matrigel-coated d35 plate (day 0) with Neu-
ral Induction Medium. The medium was refreshed daily, and the cells were passaged when they were confluent 
(day 7–9). By that time, the cells showed robust PAX6 expression and extensive reductions of pluripotent mark-
ers (POU5F1, NANOG). After passage (p), PAX6 expression in the entire cell population was further improved 
and the cell doubling time was determined by cell counting between p1 and 2 (day 8–15). RNA preparations 
and cells for immunostaining were collected between p1 and p4 (day 12–22) to ensure that both control and 
MAND iPSC lines were equally and fully differentiated into NPC stage and avoided any undifferentiated cell to 
be included (Supplementary Table 1).
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Immunostaining. Cells were grown on Lab-Tek II 4-well chambered cover glass (Nunc) coated with 
Matrigel. After fixing the cells in 4% paraformaldehyde in PBS for 10 min and permeabilizing them in 1.0% 
Triton X-100/PBS for 30 min, coverslips were placed in 5% (v/v) goat serum/5% w/v BSA in PBS for 1 h. Cells 
were then incubated with appropriately diluted primary antibodies (Supplementary Table 2) overnight at 4 °C. 
Secondary antibody staining was performed with either Alexa Fluor 568-, 647- or 488-labeled detection reagents 
(goat anti-rabbit, goat anti-mouse antibodies; Molecular Probes) at 1:300 dilution (Supplementary Table  2). 
Images were captured under an Olympus IX70 inverted microscope with an ORCA-AG CCD camera (http:// 
www. biote ch. misso uri. edu/ mcc/ Olymp us. html).
Quantitative RT‑PCR. This analysis was performed similar to previously  reported6,30. Briefly, RNA was 
isolated from control and patient NPC lines using RNeasy Plus Mini Kits (QIAGEN) according to manufac-
turer’s instructions. All samples were treated with DNAse I. RNA was quantified using the NanoDrop ND-100 
Spectrophotometer. First-strand cDNA synthesis was carried out with qScript cDNA SuperMix (Quanta Bio-
sciences) according to manufacturer’s instructions. For quantitative real-time PCR, predesigned Taqman MGB 
(minor groove binder) probes from Assays-on-Demand Gene Expression Products (Life Technologies) were 
used for all genes (see Supplementary Table 3). All samples were run in triplicate in 10 μL reaction volumes. PCR 
conditions were the default setting of the ABI Prism 7900 HT Sequence Detection System (Life Technologies). 
The cycle threshold (Ct) was determined during the geometric phase of the PCR amplification plots, as recom-
mended by the manufacturer. Relative differences in transcript levels were quantified with the ΔΔCt method 
with GAPDH as an endogenous control and were compared between control and MAND cell lines. Statistical 
analysis for gene expression differences by one-way ANOVA was performed with Prism 8.4.2 (GraphPad Soft-
ware, graphpad.com).
RNA‑seq transcriptome analysis. RNA was isolated from NPC using RNeasy Plus Mini Kits (QIA-
GEN). The quantitation and quality control of RNA from all samples were performed on a Fragment Analyzer 
(Advanced Analytical), and cDNA libraries were constructed by standard methods (Illumina TruSeq mRNA 
stranded kit) with index adapters (Illumina TruSeq indexes). All libraries were sequenced as paired-end, 50 
base read length on an Illumina HiSeq 2500 with an average read count of 21–28 million reads per sample at 
University of Missouri DNA core (dnacore.missouri.edu/). Once reads were obtained, all reads were analyzed for 
quality using FastQC (http:// www. bioin forma tics. babra ham. ac. uk/ proje cts/ fastqc/), aligned to human genome 
GRCh38 using STAR 31 and counted using  FeatureCounts32. The resulting gene-wise count matrices were used for 
downstream analyses. Differential gene expression analysis was conducted using  DeSeq233 comparing MAND 
NPC lines with control NPC lines. Of the 59,074 transcripts analyzed, 19,801 passed all DeSeq2 quality filters 
Figure 1.  MAND patient 2q23.1 deletions include MBD5 and exhibit reduced MBD5 expression indicating 
haploinsufficiency. (a) Schematic diagram of the chromosome 2q23.1 deletion region. The coding region of 
MBD5 is indicated by the red box; yellow region indicates non-coding exons. Chromosome 2q23.1 deletions 
present in the MAND patients in this study are summarized with bars. Additional details regarding MAND 
patients are provided in Supplementary Table 1. (b) qRT-PCR analysis showed ~ 50% reduction of MBD5 mRNA 
expression in primary fibroblasts derived the three MAND patients compared to the controls. Expression of 
MBD5 was calculated relative to that of the housekeeping gene, GAPDH. All expression values were calculated 
relative to control levels set at 1.0. Error bars represent the SEM. ****p < 0.0001, n = 3 independent biological 
replicates performed in triplicate, GraphPad Prism 8.4.2 (graphpad.com). (c) Overview of iPSC and neural 
progenitor cell (NPC) line derivations in this study. Skin fibroblasts from MAND patients (bar, 0.5 mm) were 
converted into iPSC by transfection with episomal plasmids encoding reprogramming factors (bar, 0.5 mm). 
NPC were derived from iPSC with neuronal induction medium (bar, 0.2 mm).
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and were given a p value. Genes were considered differentially expressed if they reached a corrected p < 0.005 
using a Benjamini–Hochberg corrected false discovery rate (FDR) α < 0.005. Data for these experiments are 
freely available at the Gene Expression Omnibus (GSE141835). The significantly differentially expressed gene set 
(498 genes shown in Supplementary Data 1) was cleaned and converted to HGNC approved gene names. The 
list was further edited for unmatched terms and synonyms resulting in a list of 468 genes (Supplementary Data 
3, Tab 1).
Gene expression network analysis: biological processes and enrichment. To identify the preva-
lent biological pathways affected in MAND due to a 2q23.1 deletion, we used four independent pathway analysis 
databases (BIOCARTA,  KEGG34,  PANTHER35 and  REACTOM36) to incorporate and assess the 468 differen-
tially expressed genes (significance cut off p = 0.05). Since each of these approaches utilize different method-
ologies and algorithms, we conducted each analysis separately to provide the most comprehensive approach to 
pathway interrogation. We also utilized Gene Set Enrichment Analysis (GSEA)37 with default parameters for 
Gene Ontology (GO) analysis of biological processes, molecular functions and pathways. To identify the enrich-
ment of the 468 differentially expressed genes by chromosomal location, we utilized  Enrichr38. This enrichment 
analysis relied on ranking the list of genes based on statistical significance with the default settings of  GSEA39.
Comparison of MAND and ASD biological processes and pathway analyses. We first compared 
the MAND differentially expressed genes list (Supplementary Data 3, Tab 1) to the SFARI database gene list 
(Supplementary Data 3, Tab 2), which is a well-curated list of 913 genes, then we expanded this list to be inclusive 
for HGNC synonyms to a final list of 944 genes. We compared the two lists to identify the overlapping genes 
(Supplementary Data 3, Tab 3) and then sought to compare the biological processes which were represented by 
each gene list using the ToppFUN  tool40 (Supplementary Data 3, Tab 4). We limited our analysis to GO: Biologi-
cal Process with a Bonferroni correction for multiple testing, a statistical p value cutoff of 0.05, and limited genes 
to 1 < n < 1500. We captured the top 50 enriched biological processes and compared them between the two lists 
(additional tables in the Tab 4). Finally, we investigated whether our MAND differentially expressed genes were 
involved in known ASD associated pathways (Supplementary Data 3, Tab 5). Pathways were visualized utilizing 
the Reactome FIViz application in  Cytoscape41 (Fig. 4c).
Results
Identification of MAND (2q23.1 deletion syndrome) patients. Three individuals with 2q23.1 dele-
tion syndrome were identified clinically by chromosomal microarray analysis (CMA) (Fig. 1a, Supplementary 
Table 1). Despite the differently sized deletions (Fig. 1a), all deletions include MBD5 exon 1, containing the 
transcription start site, as well as the MBD5 translation start site (located in exon 6), and as a consequence, all 
three patients have ~ 50% MBD5 mRNA expression (p < 0.0001) resulting in haploinsufficiency (Fig. 1b). These 
three patients have phenotypes commonly observed in MAND, including developmental delay, intellectual dis-
ability, sleep disturbance, seizures, language delay, hypotonia, mild dysmorphic features, and ASD-associated 
behaviors (short attention span and stereotypic, repetitive behaviors), consistent with the most prevalent clinical 
features of 2q23.1 deletion  syndrome5. Since the primary phenotypic concerns for patients with 2q23.1 deletion 
syndrome are neurodevelopmental, we took an approach to investigate the molecular mechanism(s) underlying 
these phenotypes by creating neural progenitor stem cells from fibroblast cell lines derived from skin biopsies 
from each patient (Fig. 1c).
Generation and characterization of iPSC derived from MAND patient fibroblasts. Skin fibro-
blast cell lines from the three MAND patients and four normal controls were developed within one month 
from the time of the biopsy. The fibroblasts were expanded, stored, and then transduced to produce iPSCs in a 
feeder-free and defined culture system (Supplementary Fig. 1). The generated iPSC colonies expressed pluripo-
tent markers, alkaline phosphatase, POU5F1 (also known as OCT4), NANOG, and TRA-1-60 (Supplementary 
Fig. 1). Programming efficiencies for MAND1-3 were 0.016, 0.4, and 0.022%, respectively. The successfully gen-
erated colonies were banked, and we utilized a subset of the iPSC lines to characterize MAND1-iPSC, MAND2-
iPSC, MAND3-iPSC (Fig. 2a,b, Supplementary Fig. 2c), and CTR1-iPSC, CTR2-iPSC, CTR3-iPSC, and CTR4-
iPSC (Supplementary Fig. 2a,b). Isolated DNAs from the iPSC lines were analyzed by chromosomal microarray 
(CMA) to confirm the molecular karyotype for each cell line was preserved and consistent with the original 
fibroblast line (Fig. 1a). Furthermore, we isolated RNA from these iPSCs and confirmed reduced MBD5 mRNA 
expression in the MAND-iPSCs (Fig. 2c).
Generation and characterization of NPCs derived from MAND‑iPSCs. Using an established neu-
ral induction monolayer culture protocols (STEMCELL Technologies)42,43, MAND and control iPSC lines were 
differentiated into PAX6 expressing NPCs (Fig. 2a,b & Supplementary Fig. 2). Expression of the pluripotent stem 
cell marker NANOG and POU5F1, which was initially expressed in 100% of the iPSCs before the differentia-
tion, had decreased to undetectable level. Another neural stem cell marker NES was expressed (Fig. 2b). Finally, 
DNA and RNA were isolated for CMA and RT-qPCR studies, respectively, to confirm cells maintained their 
original integrity during differentiation into neural lineage cells. CMAs of each NPC line were consistent with 
fibroblast and iPSC analyses, and RT-qPCR studies confirmed significantly reduced MBD5 mRNA expression in 
the MAND-NPC lines (Fig. 2d).
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Global transcriptome analysis of MAND NPC reveals genome‑wide alterations. In order to 
investigate the genes, pathways, and biological processes that are disrupted due to MBD5 haploinsufficiency that 
might provide insight into the etiology of this complex neurodevelopmental condition, we performed RNA-
seq analysis on these established NPC lines. RNA-seq analysis (n = 3 MAND-NPCs, n = 4 CTR-NPCs) initially 
identified 498 differentially expressed genes in MAND-NPCs (Fig. 3a). From these 498 genes, there was an even 
distribution of upregulated and downregulated genes, confirming that MBD5 can act as a positive and negative 
regulator of gene expression (Fig. 3b). The top differentially expressed (up and down) genes in MAND-NPCs 
compared to the Control-NPCs are depicted in a heat map (Fig. 3c). The 228 genes up-regulated in MAND-
NPCs (Fig.  3b, see Supplementary Data 2 for complete list) include those coding for a variety of transcrip-
tion factors, including FOXG1* and other F-Box, T-Box, SOX, and homeobox genes; transmembrane proteins 
(transporters, receptors), including GABRA3* and SLC30A3*; ligands (WNT7B, FGF9); and non-coding RNAs 
(VASN, RIN2, LINC01551, SOX21-AS1). The 270 down-regulated genes (Fig. 3b, see Supplementary Data 1 for 
complete list) contained transcription regulators, including MBD5*, FOXQ1, MSX2, GATA2; transmembrane 
proteins: SLC1A1*, GPR37*, OXTR*, FZD10; and ligands: NTF4, TGFB2, SMAD7. Gene names with asterisk* 
are in SFARI Gene (https:// www. sfari. org/ resou rce/ sfari- gene/) [version of June 20, 2019 released]. The initial 
Figure 2.  Generation of iPSC and NPC lines from individuals with MAND. (a) Bright-field images of 
undifferentiated iPSC lines from MAND1-3 (top row panel, l to r). Lower panel images are three NPC lines 
derived from MAND1-3 iPSC lines, respectively (l to r). After two weeks of neuronal induction, images were 
captured. Bars, 0.2 mm. (b) Immunostaining of MAND1 iPSC  (1st row) and MAND1 NPC  (2nd row) for 
neural progenitor cell marker PAX6  (1st column) and pluripotent cell marker NANOG  (2nd column and  3rd for 
merged). Immunostaining of MAND1 iPSC and MAND1 NPC for NES  (3rd and  4th rows, respectively). (c, d) 
qRT-PCR analysis confirmed ~ 50% reduction of MBD5 mRNA expression in MAND iPSC (c) and NPC lines 
(d) when compared with control iPSC and NPC lines, respectively. p < 0.0001. Quantification of the test gene 
(MBD5) was calculated relative to that of the housekeeping gene, GAPDH. All expression values were calculated 
relative to control levels set at 1.0. Error bars represent the SEM. ****p < 0.0001, n = 3 independent biological 
replicates performed in triplicate, GraphPad Prism 8.4.2 (graphpad.com).
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498 genes were assessed and converted to unique HGNC approved gene names, resulting in 468 unique genes, 
which were then used for all downstream analyses. Genome-wide expression differences as a consequence of 
the 2q23.1 deletion were examined using Enrichr, which sorted the 468 differentially expressed genes by their 
chromosome region and location. The chromosomes with the greatest number of differentially expressed genes 
were chromosomes 10, 3, 13, 18, 21, respectively (Fig. 3d, see Supplementary Data 2, Tab 1 for complete list of 
genes in the chromosome locations).
MAND is associated with alterations in multiple biological processes and pathways. To iden-
tify the biological processes that are affected by 2q23.1 deletions in MAND NPC, we utilized Gene Set Enrich-
ment Analysis (GSEA), revealing high enrichment in these 5 categories: organ morphogenesis (p = 1.24e−18), 
regulation of cell population and proliferation (p = 3.07e−16), neurogenesis (p = 3.32e−16), neuron differentiation 
(p = 7.61e−15) and central nervous system development (p = 1.52e−14) (Supplementary Data 2, Tab 4). Performing 
GO analysis with the differentially expressed genes results showed that most genes dysregulated as a consequence 
of 2q23.1 deletion were involved in transcription regulatory region DNA binding (GO: 1990837 and 0044212) 
(Supplementary Data 2, Tab 3). To identify the key pathways impacted by the 468 differentially expressed genes, 
we ran our differential gene list through BIOCARTA and PANTHER pathway databases. Overall, our gene set 
was enriched in pathways involved in signal transduction, neuronal system, developmental biology, hemosta-
sis, immune system, and disease (Supplementary Fig.  4). Key pathways that contained MAND differentially 
Figure 3.  Global transcriptome analysis of MAND NPC reveals alterations of multiple genes. (a) Scatter plot of 
fold-change in gene expression in MAND NPC lines versus control NPC lines. The gene expression difference 
between MAND and CTR NPC lines are shown in  log2 fold changes in y-axis. Genes more highly expressed 
in MAND NPC than in CTR NPC have a positive fold-change, while the down-regulated genes are illustrated 
with negative fold change. X-axis represents mean normalized expression. Significantly differentially expressed 
genes are shown in red. Some representative differentially expressed genes are indicated, including MBD5 
(circled in yellow). (b) MAND-associated 2q23.1 deletion results in both positive and negative effects on gene 
expression. The 468 differentially expressed genes are plotted based on their  log2 fold changes in y-axis. Arrows 
point to MBD5 and other genes that are associated with autism spectrum disorder (ASD). (c) Heatmap for top 
25 differentially expressed genes; the 12 most downregulated and 13 most upregulated genes in the MAND 
NPC compared with control NPC lines are shown. (d) The 468 differentially expressed genes are plotted based 
on chromosome region. Based on the combined score (Supplementary Data 2, Tab 1), the greatest number of 
differentially expressed genes were on chromosomes 10, 3, 13, 18, and 21.
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expressed genes were TGFβ and Hippo signaling pathways, receptor signaling by FGF and tyrosine kinases, 
DNA replication, and cell cycle (Fig. 4c, Supplementary Data 3, Tab 5).
Transcriptional impact of MAND‑associated 2q23.1 deletion on expression of autism‑associ-
ated genes. We queried if there was overlap between the differentially expressed genes identified via RNA-
seq in MAND NPCs and those genes known to be associated with autism. We compared MAND RNA-seq data 
to syndromic and non-syndromic ASD genes from SFARI (https:// www. sfari. org/ resou rce/ sfari- gene/) (Fig. 4a, 
Supplementary Data 3, Tab 1–3). Genes differentially expressed in MAND NPCs show overlap with 4.3% of the 
ASD associated genes from SFARI (n = 20). We then compared our list with the SFARI autism gene set utilizing 
 ToppCluster40. This analysis revealed striking significant overlap between the two gene lists on biological pro-
cesses, which are in keeping with the neurological phenotype and ASD, and include forebrain and telencephalon 
regionalization, neuron fate commitment, and forebrain development (Fig. 4b). Interestingly, processes unique 
to each gene list were also identified, which may be an area for future studies of pathogenesis for each genetic 
subgroup. Finally, we discovered that several MAND differentially expressed genes are also involved in overrep-
resented pathways commonly seen in  ASD18,44,45, including Hippo (8 genes identified in the pathway, i.e. n = 8), 
MAPK (n = 11), DNA replication/cell cycle (n = 11), and spliceosome formation pathways (n = 7) (Fig. 4c, Sup-
plementary Data 3, Tab 5), providing additional biological connections between MAND and ASD.
FOXG1 expression is significantly increased in MAND NPC. In this study, MAND NPC RNA-seq 
data revealed significantly increased FOXG1 mRNA levels over the controls, which was confirmed by RT-qPCR 
(Fig. 5a). FOXG1 is essential for the normal development of the telencephalon, which is one biological process 
that is highly enriched in the MAND NPC data set (Supplementary Fig. 3 and Fig. 4b)46,47. Pathogenic variants 
in FOXG1 are associated with autosomal dominant Rett syndrome, congenital variant [MIM 613454], which 
is characterized by normal birth but development of progressive microcephaly, severe hypotonia, midline ste-
reotypic activities typical of classic Rett syndrome, no spoken language, and electroencephalography (EEG) 
abnormalities. MBD5 (2q23.1 deletion) and FOXG1 have each been coupled with Angelman syndrome-like 
Figure 4.  Altered cellular pathways and biological processes overlap between MAND and ASD. (a) 
Differentially expressed genes identified in MAND NPC RNA-seq data were compared to the syndromic and 
non-syndromic ASD genes in the SFARI database. The genes which are differentially expressed in MAND 
NPCs show overlap with 20 ASD associated genes and biological processes. In addition, the two gene lists 
also have their own unique biological processes. (b) Biological processes affected in MAND NPCs overlap 
those also enriched the SFARI dataset. Utilizing ToppGene, we see significant enrichment for multiple 
cellular and developmental processes, with overlap with central nervous system development, neurogenesis, 
neuron differentiation, generation of neurons, and nervous system development with the SFARI gene set. 
(c) Enrichment of ASD-associated pathways in MAND NPCs. Utilizing DAVID, significantly differentially 
expressed genes in MAND NPC are enriched in the following KEGG Pathways: spliceosome, MAPK signaling, 
cell division/DNA replication and WNT signaling. The solid and broken lines represent direct and indirect 
interactions, respectively. The arrow indicates activation, while a T head shows repression in the interaction.
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(AS-L) cohorts and Rett syndrome-like cohorts (RS-L)48. Further, duplication of FOXG1 is associated with West 
syndrome, a neurodevelopmental syndrome that includes epilepsy, developmental delays, and severe speech 
 impairment46,49,50, similar to the phenotype observed in MAND. Increased FOXG1 expression was also noted in 
ASD proband forebrain organoids over the control organoids, and down regulation of FOXG1 in the organoid 
rescued the ASD-associated  phenotype51. We compared the growth of MAND NPCs to CTR NPC and found 
that the doubling time of MAND NPC was significantly slower than CTR NPC (Fig. 5b). Overall, 2q23.1 dele-
tion results in de-repression of FOXG1 and other genes, including SOX11, EZH2, EED, ETV5, and KDM1A, 
which all function as chromatin modifiers and are implicated in neurogenesis (Supplementary Data 2, Tab 4), 
further connecting this network of epigenetic modifiers and their critical roles in neurodevelopment.
Discussion
Investigation and understanding of neurodevelopmental disorders has been fueled by the development of iPSC 
from patients with these complex genetic  conditions14. In this study, we generated and characterized iPSCs and 
NPCs that were derived from MAND (2q23.1 deletion syndrome) patients with overlapping phenotypes of ID 
and autism. By utilizing global transcriptome analysis, we were able identify differentially expressed genes in 
early neuronal development that are associated with pathways and genes common to ASD. These findings sup-
port previous knowledge about the functional role of MBD5 but also provide new insights into the consequences 
of chromosome 2q23.1 deletion in the regulation of numerous pathways that when altered contribute to the 
phenotype in 2q23.1 deletion syndrome.
In this study, cells were directly collected from patients with MAND and converted to iPSCs and NPCs. This 
approach allowed us to recapitulate the gene dosage effects in early neuronal developmental stages in human 
cells. There are advantages of our model compared to previous models to understand MAND. A previous study 
using an Mbd5 gene-trap mouse model showed abnormal behavior and cognitive  impairment9; however, this 
Mbd5 gene-trap model is not representative of human 2q23.1 deletion syndrome. Another study utilized primary 
human neural precursor cells that were treated by a short hairpin RNA (shRNA) to suppress MBD5  expression52; 
however, this methodology resulted only in a single cell line with reduced MBD5 expression, limiting the analysis 
of data. In the most recent study, Seabra et al. (2020) generated CRISPR-derived neurons with mutation of MBD5 
and then conducted RNA-seq53. However, MBD5 was not sufficiently dysregulated in the study; thus, the data 
presented are not truly representative of  MAND53. The present study utilizing patient-derived NPC provides a 
representative disease model, consistent with other recent ASD studies that have shown the advantages of using 
iPSC technology for the study of genetic impact on human early neuronal developmental  stage54.
Previous studies have shown that 2q23.1 deletions are critical for neurodevelopment and that MBD5 haplo-
insufficiency is responsible for phenotypes, such as seizures, sleep, speech impairment, and  autism5–7,30,55. These 
studies fell short in identifying the exact targets of MBD5 and the perturbed biological processes and pathways 
consequent to MBD5 haploinsufficiency that could explain these neurodevelopmental phenotypes. In our study, 
we recognize that the dysregulated genes and pathways identified may not necessarily be due to direct effects of 
MBD5 haploinsufficiency alone and could be due to indirect, downstream effects of reduced MBD5 expression 
or may be due to reduced expression of other deleted gene(s) in these patient samples. Additional molecular 
studies are required to understand the effect of MBD5 haploinsufficiency specifically on these dysregulated genes. 
Differentially expressed genes in NPC of MAND patients included genes associated with other neurodevelop-
mental disorders (Figs. 3, 4). A study of pathogenic de novo mutations that link to intellectual disability identified 
Figure 5.  MAND-associated 2q23.1 deletion including MBD5 results in de-repression of FOXG1. (a) 
Altered expression of FOXG1 in MAND NPCs. Quantitative real-time PCR was performed on MAND NPC 
and control NPC lines. Levels of FOXG1 mRNA were calculated relative to that of the housekeeping gene 
GAPDH. All expression values were calculated relative to control levels set at 1.0. Error bars represent the SEM. 
****p < 0.0001, n = 3 independent biological replicates performed in triplicate. (b) Comparison of cell doubling 
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mutations in genes identified in our data set: FOXG1, MBD5, TBR1, GABRB3 and  others56 (Supplementary Data 
3, Tab 3). By the Gene Ontology (GO) enrichment analysis of the transcriptome data, biological functions of 
neuron development, brain development and cellular processes were altered in the cohort in alignment with the 
neurodevelopmental phenotype present in these individuals (Supplementary Fig. 3).
In this study, we took advantage of the ability to derive NPCs from MAND patient cells and RNA-seq analysis 
to investigate the role of MAND on ASD-associated genes and pathways (Figs. 3, 4). Studies of ASD patient-
derived neuronal cells have demonstrated altered gene expression and dysregulation of pathways such as Hippo, 
MAPK, DNA replication/cell cycle, and spliceosome formation  pathways57,58. While our study may have been 
hindered by small sample size, our analysis using the SFARI database identified 20 genes (4.3%) linked to 
ASD with altered gene expression due to 2q23.1 deletion, highlighting the commonalities between the MAND 
and ASD (Fig. 4a). This percentage is similar to the enrichment for SFARI genes in other key ASD RNA-seq 
 studies44,57–59. These genes could be the key to understanding the connection between MAND and autism. 
Further, six key biological processes are shared between our data set and genes with known association to ASD 
(Fig. 4b), suggesting that these biological processes are key to understanding the overlapping phenotypes between 
MAND and ASD. Further study of these biological processes is needed to more clearly elucidate the physiological 
mechanisms that are altered.
The MAND-derived NPC RNA-seq data revealed differentially expressed genes previously linked to neu-
rodevelopmental disorders. Some of the most interesting connections in phenotypically similar neurodevel-
opmental disorders include the FOXG1 dosage-linked associations with Rett syndrome and West syndrome. 
Our findings in this study indicate that MBD5 either directly or indirectly regulates FOXG1 expression in an 
early neurogenesis stage (Fig. 5). Mutation and/or altered expression of FOXG1 have been shown to cause an 
autosomal dominant form of Rett  syndrome60, associated with  ASD59, West  syndrome50, and  schizophrenia61. 
Since FOXG1 is a dosage sensitive gene, its overexpression would likely affect proper brain development and 
cognitive functions. Furthermore, this may represent a possible route for convergent phenotypes between MAND 
and other syndromes, including West syndrome associated with duplication of FOXG150. The slow growth of 
MAND NPCs (Fig. 5b) may represent a link between FOXG1 dysregulation and improper glutathione synthesis. 
CHAC2 expression is also altered in our dataset (Supplementary Data 1). CHAC2 is thought to be essential for 
glutathione  maintenance62,63. Interestingly, FOXG1 plays a role in the transcriptional repression of CHAC1 which 
is in the same family as CHAC2 and also plays a role in glutathione maintenance (Fig. 6). CHAC1 is thought 
be a pro-apoptotic factor and inhibitor of NOTCH signaling in glioblastoma cell  lines64. Further, FOXG1 is 
thought to play a role in glutathione maintenance and glutathione is thought to regulate cell  proliferation65,66. 
Future molecular studies to assess MBD5 regulation of FOXG1 is necessary especially in relation to glutathione 
synthesis and Notch signaling (Fig. 6).
Here, our study of MAND with human neural in vitro cultures through patient-derived NPC demonstrates 
FOXG1 upregulation (Fig. 5), as well as perturbed expression of genes implicated in brain development, especially 
forebrain regionalization (Fig. 4b), and affected genes significantly overlap with ASD associated genes (Fig. 4a). 
These findings expand our knowledge about gene network differences and possible interactions between these 
related disease pathways (Figs. 4c, 6). Such findings may lead to potential connections between overlapping 
neurocognitive and neuropsychiatric phenotypes and associated risk factors, such as other chromatin modi-
fiers and epigenetic factors that link to ASD. We expect these in vitro models will nurture hypotheses toward 
therapeutic  interventions67,68.
Web resources
The URLS for data present herein are as follows:
AutismKB, http:// autis mkb. cbi. pku. edu. cn/.
Cytoscape, http:// www. cytos cape. org/.
DAVID Bioinformatics Resources 6.7, http:// david. abcc. ncifc rf. gov/.
Enrichr, http:// amp. pharm. mssm. edu/ Enric hr/.
GSEA (Gene Set Enrichment Analysis), https:// www. gsea- msigdb. org/ gsea/ index. jsp.
KEGG, http:// www. genome. jp/ kegg/.
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Online Mendelian Inheritance in Man (OMIM), http:// www. omim. org/.
PANTHER, http:// www. panth erdb. org.
SFARI Human Gene Module (accessed February 18, 2020), https:// gene. sfari. org/ autdb/ HG_ home. do.
ToppCluster https:// toppg ene. cchmc. org/.
UCS Genome Browser, http:// genome. ucsc. edu.
Data availability
The RNA-seq data are available in the Gene Expression Omnibus (GSE141835).
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